공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

심상성 천포창 : 파이프라인 리뷰

Pemphigus Vulgaris (Immunology) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 213128
페이지 정보 영문 88 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


심상성 천포창 : 파이프라인 리뷰 Pemphigus Vulgaris (Immunology) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 88 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

심상성 천포창은 희귀한 자가면역질환으로, 통증이 있는 수포가 피부 또는 점막에 발생합니다. 인종, 성별, 연령 등이 위험인자로, 증상은 통증을 수반하는 수포가 입안을 시작으로 발생하거나 상실됩니다. 수포는 일반적으로 피부 표면 부근에 나타나며, 체액의 삼출, 가피 형성, 피부 박리 등을 볼 수 있습니다.

심상성 천포창(Pemphigus Vulgaris) 치료제의 개발 상황에 대해 조사분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 관한 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

심상성 천포창 개요

치료제 개발

  • 파이프라인 제품 개요
  • 기업별 파이프라인
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여 기업

  • Almirall SA
  • Biogen Inc
  • HanAll Biopharma Co Ltd
  • Immunomedics Inc
  • Novartis AG
  • Principia Biopharma Inc

약제 개요

심상성 천포창 : 휴지중인 프로젝트

심상성 천포창 : 개발이 중지된 제품

심상성 천포창 : 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

LSH 17.06.30

List of Tables

List of Tables

  • Number of Products under Development for Pemphigus Vulgaris, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pemphigus Vulgaris - Pipeline by Argenx SE, 2021
  • Pemphigus Vulgaris - Pipeline by Biogen Inc, 2021
  • Pemphigus Vulgaris - Pipeline by BioXpress Therapeutics SA, 2021
  • Pemphigus Vulgaris - Pipeline by Cabaletta Bio Inc, 2021
  • Pemphigus Vulgaris - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
  • Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co Ltd, 2021
  • Pemphigus Vulgaris - Pipeline by iBio Inc, 2021
  • Pemphigus Vulgaris - Pipeline by Octagon Therapeutics Inc, 2021
  • Pemphigus Vulgaris - Pipeline by Pharmapraxis, 2021
  • Pemphigus Vulgaris - Pipeline by Topas Therapeutics GmbH, 2021
  • Pemphigus Vulgaris - Dormant Projects, 2021
  • Pemphigus Vulgaris - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Pemphigus Vulgaris, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pemphigus Vulgaris - Drugs In Development, 2021, provides an overview of the Pemphigus Vulgaris (Immunology) pipeline landscape.Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pemphigus Vulgaris - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Pemphigus Vulgaris (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pemphigus Vulgaris (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Pemphigus Vulgaris - Overview
  • Pemphigus Vulgaris - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Pemphigus Vulgaris - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Pemphigus Vulgaris - Companies Involved in Therapeutics Development
  • Argenx SE
  • Biogen Inc
  • BioXpress Therapeutics SA
  • Cabaletta Bio Inc
  • Daewoong Pharmaceutical Co Ltd
  • HanAll Biopharma Co Ltd
  • iBio Inc
  • Octagon Therapeutics Inc
  • Pharmapraxis
  • Topas Therapeutics GmbH
  • Pemphigus Vulgaris - Drug Profiles
  • batoclimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DWP-212525 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • efgartigimod alfa - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target DSG1 and DSG3 for Mucocutaneous Pemphigus Vulgaris - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Target DSG3 for Pemphigus Vulgaris - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OW-177 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biobetter - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rituximab biosimilar - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TPM-203 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pemphigus Vulgaris - Dormant Projects
  • Pemphigus Vulgaris - Discontinued Products
  • Pemphigus Vulgaris - Product Development Milestones
  • Featured News & Press Releases
  • Aug 18, 2021: Cabaletta Bio reports clinical data from the second dose cohort in DesCAARTes trial in patients with mPV
  • May 03, 2021: Cabaletta Bio reports acute safety data from the first dose cohort in DesCAARTes trial
  • Dec 08, 2020: Cabaletta Bio announces first patient dosed in Landmark DesCAARTes trial of DSG3-CAART for treatment of mucosal-dominant pemphigus vulgaris
  • Aug 25, 2020: Cabaletta Bio announces publication of comprehensive preclinical study results for DSG3-CAART in pemphigus vulgaris
  • May 06, 2020: Cabaletta Bio receives FDA Fast Track Designation for DSG3-CAART for the treatment of Mucosal Pemphigus Vulgaris
  • Jan 29, 2020: FDA grants DSG3-CAART orphan drug designation for the treatment of pemphigus vulgaris
  • Dec 18, 2019: Topas Therapeutics announces first patient enrolled in phase 1 trial with TPM203 in pemphigus vulgaris
  • Oct 14, 2019: Roche's Rituxan outperforms MMF in pemphigus vulgaris study
  • Oct 01, 2019: Cabaletta Bio receives IND clearance from FDA to initiate first clinical trial of DSG3-CAART in patients with Mucosal Pemphigus Vulgaris
  • Jun 12, 2019: Phase III PEMPHIX study showed that Genentech's Rituxan (Rituximab) is superior to standard of care in achieving sustained remission in patients with Pemphigus Vulgaris
  • Mar 15, 2019: EC approves Roche's MabThera for pemphigus vulgaris
  • Jan 31, 2019: CHMP recommended extension of indication for Mabthera
  • Dec 12, 2018: Cell therapy industry pioneer, Gwendolyn Binder, Ph.D., to join Cabaletta Bio leadership team
  • Jul 24, 2018: argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation
  • Jun 20, 2018: argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q